Although the ResAppDx algorithm which has been extended for COVID-19 is technically still in a development phase, Pfizer has committed to the R&D license agreement for it which is separate to the proposed scheme so I wouldn't call this minimal focus and RAP is getting excellent PR from it.....
Shareholder Registry, page-16
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
